НЕЖЕЛАТЕЛЬНЫЕ ЯВЛЕНИЯ ИНТЕРФЕРОНОВ СИСТЕМНОГО ДЕЙСТВИЯ
Аннотация
Ключевые слова
Об авторах
Александр Андреевич ТопоровРоссия
Алексей Сергеевич Колбин
Россия
Список литературы
1. Fried M. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5): 237-44.
2. Chevaliez S., Pawlotsky J.M. Interferons and their use in persistent viral infections. Handb Exp Pharmacol. 2009; (189): 203-41.
3. Gaeta G., Precone D., Felaco F. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2002; 16(9): 1633-1639.
4. Witthöft T., Мüller K., Wiedmann K. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronichepatitis C in clinical practice: the german open safety trial. J Viral Hepat. 2007; 14(11): 788-796.
5. Middleton M., Hauschild A., Thomson D. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-a2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann. Oncol. 2007; 18(10): 1691-1697.
6. Anil J., Anjum J., Saad K. Tropical Gastroenterology. 2009; 30(3): 175-176.
7. Anil J., Saad K., Emadi S. et al. Polymyositis during pegylated alpha interferon ribavirin therapy in chronic hepatitis. Indian J Gastroenterol. 2007; 26: 147-8.
8. Cirigliano G., Rossa A., Tavoni A. Polymyositis occurring during alpha interferon treatment for malignant melanoma-a case report. Rheumatol Int. 1999; 19: 65-7.
9. Dietrich L., Bridges A., Albertini M. Dermatomyositis after interferon alpha treatment. Med Oncol. 2000; 14; 64-9.
10. Максимов В.А. Виферон против HCV. Опыт использования. / В.А. Максимов; В.А. Неронов; С.Н. Зеленцов; С.Д. Карабаев // Эффективная фармакотерапия. 2010 - № 1(12) - с. 10-15.
11. Serra D., Sun H., Karwowska S. Single-Dose Pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. Antimicrob Agents Chemother. 2011; 55(2): 473-477.
12. Bhattacharya D., Umbleja T., Carrat F. Women Experience Higher Rates of Adverse Events During HCV Therapy in HIV Infection: A Meta-Analysis. J Acquir Immune Defic Syndr. 2011; 55(2): 170-175.
13. Еналеева Д.Ш. Сравнительная характеристика нежелательных явлений на противовирусную терапию у пациентов с хроническим гепатитом С. / Д.Ш. Еналеева; Э.Р. Манапова; С.В. Ткачева; Ю.В. Фазылова // Практическая медицина. 2012 - № 1(12). с. 2-23.
14. Markowitz C., Patel P., Boateng F. Combined effect of nursing support and adverse event mitigation on adherence to interferon beta-1b therapy in early multiple sclerosis. J MS Care. 2012; 14(4): 198-208.
15. Freedman M. Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis. Expert Opin Biol Ther. 2014; 14: 1207-1214.
16. Comi G., Filippi M., Barkhof F. et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet. 2001; 357: 1576-82.
17. Sapra S., Chang E., Broder M. et al. Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Services Research. 2014; 14: 429.
18. Wang K., Xing H., Zhao H. et al. Efficacy and tolerability of low-dose interferon-a in hemodialysis patients with chronic hepatitis C virus infection. WJG. 2014; 20(14): 4071-4075.
19. Manceau P., Latarche C., Pittion S. et al. Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. BMC Neurology. 2014; 14: 215.
20. Schellekens H., Casadevall N. Neutralizing antibodies falling on treatment of multiple sclerosis with interferon beta-1b: experience falling on the first three years. Neurology. 1996; 47(4): 889-894.
21. Sorensen P., Ross C., Clemmesen K. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362 (9391): 1184-1191.
22. Malucchi S., Sala A., Gilli F. Neutralizing antibodies reduce the efficacy of IFN beta during treatment of multiple sclerosis. Neurology 2004; 62(11): 2031-2037.
23. Sato D., Nakashima I., Fukazawa T. Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients. Tokohu J Exp Med. 2012; 228(2): 85-92.
24. Clemens M.J. Interferons and apoptosis. J Interferon Cytokine Res. 2003; 23: 277-292.
25. Pedersen I.M., Cheng G., Wieland S. et al. Interferon modulation of cellular microRNA as an antiviral mechanism. Nature. 2007; 499: 919-922.
26. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001; 19: 65-91.
27. Pichler W.J. Adverse side-effects to biological agents. Allergy. 2006; 61(8): 912-20.
Рецензия
Для цитирования:
Топоров А.А., Колбин А.С. НЕЖЕЛАТЕЛЬНЫЕ ЯВЛЕНИЯ ИНТЕРФЕРОНОВ СИСТЕМНОГО ДЕЙСТВИЯ. Безопасность и риск фармакотерапии. 2015;(2):5-11.
For citation:
Toporov A.A., Kolbin A.S. ADVERSE EVENTS OF INTERFERONS WITH SYSTEMIC EFFECT. Safety and Risk of Pharmacotherapy. 2015;(2):5-11. (In Russ.)